Public consultation on proposed amendments to the Poisons Standard - ACMS, ACCS and Joint ACMS-ACCS, November 2021

Closed 7 Oct 2021

Opened 6 Sep 2021

Contact

Medicines Scheduling

1800 020 653

medicines.scheduling@health.gov.au

Feedback updated 1 Dec 2022

We asked

Between 6 September 2021 to 7 October 2021, we sought submissions from the public on scheduling proposals referred to the November 2021 meetings of the Advisory Committees on Medicines and Chemicals Scheduling. Respondents were given the choice to indicate their support or opposition to the proposed amendments using survey buttons, with or without a written response.

You said

We received a total of 402 responses, 284 with written components. The majority of submissions were in relation to the proposal for meloxicam.

The number of votes in opposition of the proposal for meloxicam was 305, there were 3 votes partially supporting the proposal and 21 in full support. Of those in opposition, 97% indicated they were health professionals and/or researchers, predominately from the veterinary industry.

The consultation for cannabis and THC received a total of 116 responses. Of these responses, 11 were opposed, 16 were in partial support and 79 votes were in support of the proposal. The votes in support of the proposal were mainly from responders who had indicated that they were health professionals and researchers.

The total number of votes received for choline salicylate was 28. There were 7 votes in opposition 6 votes in partial support and 15 votes fully supporting the proposal.

There was a total of 23 votes in response to the proposal for cis-jasmone. The number of votes in opposition was 4 followed by 2 votes in partial support and 17 votes fully supporting the proposal.

For astodrimer, a total of 41 votes were received. The votes in opposition and in full support were even, both with 17 votes each, and the remaining 7 votes in partial support for the proposal.  Of the votes in opposition, the majority of respondents indicated that they were health professionals/researchers.

There was a total of 35 submissions for flurbiprofen, 13 in opposition, 4 in partial support and 18 in full support of the proposed amendments.

A total of 21 votes were received with respect to chromates and chromium trioxide. Of these votes, 6 voted in opposition, 2 in partial support and 13 in support of the proposed amendments.

We did

The Delegate considered all submissions prior to making their interim decisions on these proposals. The interim decisions on the proposed amendments to the Poisons Standard were published on 10 March 2022.

Published responses

View submitted responses where consent has been given to publish the response.

Overview

Scheduling amendments referred to expert advisory committee

This pre-meeting consultation is for applications and delegate initiated proposals to amend the Poisons Standard. The scheduling amendments and any submissions received will be considered at the November 2021 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).

The closing date for this consultation is close of business 7 October 2021. All submissions received by the deadline will be considered by the delegate before they make an interim decision.

The proposals under consultation are detailed in the public notice of September 2021.

Substances for which public comment is sought

  • Item 1.1 - Astodrimer sodium
  • Item 1.2 - Flurbiprofe
  • Item 2.1 - Chromates and chromium trioxide
  • Item 3.1 - Cis-jasmone
  • Item 3.2 - Cannabis and tetrahydrocannabinols
  • Item 3.3 - Meloxicam
  • Item 3.4 - Choline salicylate

What happens next

All public submissions will be published on the TGA website at Public submissions on scheduling matters, unless marked confidential or indicated otherwise in the submission information (see Privacy and your Personal information).

Public submissions are an important part of the process for amending the Poison Standard, and are published on the TGA website using the consultation hub.  Submissions by the public may not reflect the views of the Department of Health or TGA.  Published submissions should not be taken as being endorsed by the Department or TGA.

Following consideration of public submissions received before the closing date and advice from the expert advisory committee/s, decisions on the proposed amendments are anticipated to be published as interim decisions on the TGA website: Scheduling delegate's interim decisions & invitations for further comment in January 2022.

Audiences

  • General public

Interests

  • Legislation